ISA Pharmaceuticals has successfully completed several clinical trials of its product candidates. These studies were performed in close collaboration with academic partners, Leiden University Medical Center (LUMC) and the University Medical Center Groningen (UMCG), and have resulted in an exciting clinical proof-of-concept in vulvar intraepithelial neoplasia (VIN) and proof-of-principle in cervical cancer.
The results of ISA’s clinical proof-of-concept trial in VIN patients have been published in the New England Journal of Medicine (Kenter et al., 2009: 361, 1838-1847) and in PNAS (Welters et al., 2010: 107, 11895-11899). The results have sparked worldwide interest in ISA’s unique SLP® technology in the immunotherapy community and the pharmaceutical industry.
In 2013, ISA announced the launch of its AMPLIVANT® technology which is based on a proprietary and synthetic small molecule TLR1/2 ligand with enhanced immunostimulatory activity. AMPLIVANT® is designed to further enhance the activity of ISA’s SLP® immunotherapeutics. The safety and immunogenic capacities of SLP®-AMPLIVANT® conjugates are currently being assessed in a phase I/II academic trial in an patients with HPV16 positive head and neck cancer.
ISA currently has ISA101 in clinical development, a synthetic long peptide immunotherapeutic for the treatment of human papilloma virus type 16 induced diseases, including cervical cancer, most ano-genital premalignant and malignant lesions, and head and neck cancer.
A recent co-authored publication in Nature (Gubin et al. Nov-2014) showed that in mice synthetic long peptides (SLP®s) are capable of effectively mounting a T-cell mediated immune response against mutation-derived neo-antigens, resulting in clinical benefit.
With more than a decade of experience with SLP® technology and recent technological advancements, ISA has started to develop personalized SLP® immunotherapy treatments in order to advance effective and affordable treatment options in large indications such as lung cancer, bladder cancer and melanomas.